NEPA is a novel oral fixed-dose combination of netupitant ( NETU ) , a new highly selective neurokinin-1 ( NK1 ) receptor antagonist ( RA ) and palonosetron ( PALO ) , a pharmacologically and clinically distinct 5-hydroxytryptamine type 3 ( 5-HT3 ) RA .